Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Longjin Tonglin is a Traditional Chinese Medicine (TCM) formulation, typically administered as a capsule, used primarily for the treatment of chronic prostatitis and benign prostatic hyperplasia (BPH). It is a multi-herbal product that standardly includes ingredients such as Gentianae Radix et Rhizoma (Longdan), Lysimachiae Herba (Jinqiancao), Phellodendri Chinensis Cortex (Huangbai), Anemarrhenae Rhizoma (Zhibu), and Plantaginis Semen (Cheqianzi). The formulation is designed according to TCM principles to clear heat, resolve dampness, and promote diuresis, thereby addressing urinary symptoms such as frequency, urgency, and pain. Clinical research, including studies conducted at Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, has also evaluated its effectiveness in improving semen abnormalities associated with chronic prostatitis. It is manufactured by pharmaceutical companies in China, most notably Kunming Longjin Pharmaceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Longjin Tonglin.